Enalapril Maleate Tablets, 20 mg recall — JB Chemicals And Pharmaceuticals Ltd (Class II)
JB Chemicals And Pharmaceuticals Ltd is recorded by the U.S. Food and Drug Administration (FDA) as recalling Enalapril Maleate Tablets, 20 mg — a Class II recall, initiated 2026-04-23 and posted to the FDA enforcement report on 2026-05-13, under recall number D-0520-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test”. From the product description, the form is tablets, the strength given is 20 mg, the package is described as 1,000-count bottle and it is marked Rx only. 1 National Drug Code number is printed in the record: 64980-688-10. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in India. It is the only recall number the FDA has filed under event ID 98794. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0520-2026 |
|---|---|
| FDA event ID | 98794 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | JB Chemicals And Pharmaceuticals Ltd |
| Recall initiated | 2026-04-23 |
| Reported by FDA | 2026-05-13 |
| Report lag | 20 days from initiation to report |
| Distribution | Nationwide in the USA — Nationwide (US) |
| Firm location on record | India |
| Product description (source) | Enalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 64980-688-10. |
Reason reported by FDA
Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
11 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
7 identifying values matched by exact pattern in the 39-word product description above; each is a literal substring of it.
| Product named | Enalapril Maleate Tablets |
|---|---|
| Form | Tablets |
| Strength | 20 mg |
| Package | 1,000-count bottle |
| NDC | 64980-688-10 |
| Marketing category | Rx only |
| Manufactured by | Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030 |
| Distributed by | Rising Pharma Holdings, Inc. |
Other indexed recalls from JB Chemicals And Pharmaceuticals Ltd
2 indexed records name JB Chemicals And Pharmaceuticals Ltd as the recalling firm, across 2 FDA events, reported 2026-05-13 to 2026-07-29. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Cetirizine Hydrochloride Tablets USP 5 mg | D-0732-2026 | Class I | 5 mg · Tablets | 2026-07-29 |
Other Class II recalls with India on record
27 indexed records carry India as the recalling firm's country, against a dataset that is predominantly United States. These are the ones that also share this recall's FDA tier.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Methohexital Sodium for Injection, 500 mg | D-0662-2026 | Onesource Specialty Pharma Ltd | 500 mg · for Injection | 2026-07-15 |
| Pemetrexed for Injection 100mg/Vial | D-0671-2026 | Reliance Life Sciences Private Ltd | 100mg/Vial · for Injection | 2026-07-15 |
| Pemetrexed for Injection 500mg/Vial | D-0672-2026 | Reliance Life Sciences Private Ltd | 500mg/Vial · for Injection | 2026-07-15 |
| Bortezomib for Injection 3.5mg/Vial | D-0673-2026 | Reliance Life Sciences Private Ltd | 3.5mg/Vial · for Injection | 2026-07-15 |
| Azacitidine for Injection 100mg/Vial | D-0674-2026 | Reliance Life Sciences Private Ltd | 100mg/Vial · for Injection | 2026-07-15 |
| Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), 1 KG | D-0691-2026 | Shimoga Chemicals | 1 KG | 2026-07-15 |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| DELFLEX, 1.5% | D-0512-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| DELFLEX, 2.5% | D-0513-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 30 mg | D-0514-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 60 mg | D-0515-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 20 mg | D-0516-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| BD PurPrep, 8.3% | D-0517-2026 | Carefusion 213, LLC | Class II | 2026-05-13 |
| BD PurPrep, 8.3% | D-0518-2026 | Carefusion 213, LLC | Class II | 2026-05-13 |
| Octreotide Acetate for Injectable Suspension, 30 mg | D-0519-2026 | Teva Pharmaceuticals Usa, Inc | Class II | 2026-05-13 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 1 nearest to 2026-05-13 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Duloxetine Delayed-Release Capsules USP, 60mg | D-0522-2026 | Breckenridge Pharmaceutical, Inc. | 60mg · Delayed-Release Capsules | 2026-05-13 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 64980-688-10 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); JB Chemicals And Pharmaceuticals Ltd (2 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0520-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0520-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-13
- Ingested
- 2026-08-22
- Record hash
6418b6c8a8d0b855
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.